Recent Updates
Recently added Catalysts
TNDM Neutral Sentiment

Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026

Key Takeaway: Tandem Diabetes Care has scheduled the announcement of its financial results for the second quarter of 2026 on August 6, 2026. This announcement is part of the company's regular reporting schedule. Further details regarding the financial performance will be provided at that time.
Price reaction · baseline $15.83 (2026-06-29 close) · hit pre-market · 1 other TNDM headline(s) in the window, move may be shared
day 0 close · peak
-4.7%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~39 mo
Minimal dilution risk
Lead asset
tozadenant
Phase 1 · N/A, as Healthy Volunteers

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial markets close on Thursday, August 6, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2026 financial and operating results.
A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located athttp://investor.tandemdiabetes.comin the “Events & Presentations” section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI09573d6a4f904373b71317b8eab87d1b) and you will be provided with dial-in details, including a personal pin.
An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located athttp://investor.tandemdiabetes.comin the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.
Tandem Diabetes Care, the Tandem logo, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries.
Last updated: Jun 30, 2026